

Message

From: Adam Rosendorff [/O=THERANOS ORGANIZATION/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=ADAM ROSENDORFD92]
Sent: 1/16/2014 7:54:07 PM
To: Sharada Sivaraman [ssivaraman@theranos.com]; Erika Cheung [echeung@theranos.com]
Subject: RE: QC for EDISONS

Thanks-

What should we do in cases where we get dark counts with the QC runs? Then we would be more limited in choosing which cartridges to disregard.

Adam

From: Sharada Sivaraman
Sent: Thursday, January 16, 2014 11:52 AM
To: Adam Rosendorff; Erika Cheung
Subject: RE: QC for EDISONS

Yes I do agree with you that intra Cvs are not relevant. I was highlighting to you that when evaluated independently each cartridge has tight Cvs in both Conc and RLU regimes which indicates that the assay itself does not have imprecision.

At this time our outlier removal procedure is manual (we can remove 2 out of the 6 data points) and it also depends on the dataset. See example below from the original dataset that Erika sent out.

I chose the cartridges in green for exclusion since they improved conc CVs.

Patient ID/Gender	Date /Time	Barcode	Reader	All		Dark				Inter-		Calibration	Concentration		Mean
				Tip	Tip	Exclusion	Intra-Cartridge		Cartridge		Tip1		Tip2		
				1	2	1	2	Mean	%CV	Mean	%CV		Tip1	Tip2	
QC Level 1	4164 9	928245663 500300317	E00	68	65	68	672	0.03	633	0.06	15.1	11.9	17.2		
			010	655	85	59	85	21.	426	88.3	940	485	912	344	
			1	93	0	3	0	5	1	3	6	2	7	4	
			E00		66	57	66	618	0.09			22.8	14.5		
			023	574	19	47	19	33.	970			275	758		
			0	74	3	4	3	5	8			3	2	5	
		E00		63	59	63		0.04			21.3	17.3			
		928245663 500300319	031 2	590 05	21 5	00 5	21 5	611 10	871 4			677 4	976 9		

			E00		71	67	71	694	0.05		0.12		13.7	8.80	19.5
QC Level	4164	928245663	023	670	93	01	93	72.	010	609	567		898	538	162
1	9	500300329	0	11	4	1	4	5	7	64	9	3	1	3	2
			E00		61	50	61	558	0.13				29.7	19.3	
		928245663	010	505	19	50	19	45.	534				574	033	
		500300330	1	01	0	1	0	5	2			3	3	6	
			E00		59	56	59		0.03				24.1	21.3	
		928245663	031	561	00	14	00	575	519				118	658	
		500300331	2	41	7	1	7	74	9			3	9	4	
			E00		34	25	34	300	0.19	326	0.10		66.0	50.2	52.7
QC Level	4165	928245663	010	258	14	87	14	09.	507	35.3	470		542	970	647
2	0	500300341	1	70	9	0	9	5	6	3	2	3	2	9	2
			E00		35	34	35	348	0.01				49.6	48.7	
		928245663	031	345	13	55	13	42.	166				590	714	
		500300342	2	55	0	5	0	5	9			3	3	2	
			E00		32	33	32		0.00				51.7	52.3	
		928245663	023	332	88	22	88	330	735				844	525	
		500300343	0	26	2	6	2	54	9			3	9	8	

I believe an algorithm for outlier removal has been incorporated in the software app process when evaluating clinical samples in Normandy.

Karthik in Daniel's group can give you details of this protocol/algorithm.

Thanks,

Sharada

=====

PRIVILEGED AND CONFIDENTIAL COMMUNICATION

IMPORTANT -- This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which they are addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.

Theranos, Inc., 1601 S. California Ave, Palo Alto, CA 94304
650-838-9292 www.theranos.com

=====

From: Adam Rosendorff
Sent: Thursday, January 16, 2014 11:14 AM
To: Sharada Sivaraman; Erika Cheung
Subject: RE: QC for EDISONS

Sharada

Since 3 devices are being used as one testing system, for the purposes of QC we must consider them as one testing system/device. Therefore the within cartridge CV is not relevant. As you are aware, we are calculating the mean of the 6 measurements (or minimum 4) to come up with the assay value, and the SD between the means to come up with the %CV (SD/mean).

In considering QC, if the CVs are very high or the ranges overlap, which 2 data points (which 1 out of 3 cartridges) should we remove from the dataset for QC going forward? IS there a protocol for this?

Thanks,

Adam

From: Sharada Sivaraman
Sent: Thursday, January 16, 2014 9:39 AM
To: Adam Rosendorff; Erika Cheung
Subject: RE: QC for EDISONS

Hi Adam,

The Cvs are high between devices, if you see for the data in the daily QC the within cartridge Cvs are really tight.

Since we are allowed to remove 2 data points from 6 (1 cartridge out of 3), I have attempted to do that with both the level 1 and 2 data and it improves things. See attached file and

also see below table with revised QC ranges. We still pass.

	Mean	SD	2SD	Low	Hi	%CV
Level 1	18.49	5.009772	10.01954	8	29	27
Level 2	45.40	5.390087	10.78017	35	56	12

Erika please confirm but it appears that we have used the calibration in tab "Dexter 3" that is the calibration for these set of readers (101, 230, 312).

If this is correct then precision/accuracy at LLOQ and ULOQ are within acceptance criteria. See below:

Model Type	LogLin 4PL					Date	10-Jan-14
Model Equation	$\log_{10}(\text{RLU}) = b1 + (b2 - b1) / (1 + (\text{Conc}/b3)^{b4})$					Name	UD
Calibration Equation						Cartridge Lot	Set #1
						Analyte	Vitamin D
						Units	ng/mL
						Cartridge Id	Set #1
						Dilution	1.00
						Reagent Lot	1
						desired LLOQ	10.00
						desired ULOQ	300.00
						max LLOQ	10.00
						min ULOQ	300.00
LLOQ	10.00	ng/mL	Model Parameters	SE			
ULOQ	300.00	ng/mL	b1	3.497	0.056		
desired LLOQ	10.00	ng/mL	b2	4.890	0.025	Data Grouping	by tip
desired ULOQ	300.00	ng/mL	b3	101.363	5.866		
LLOD	Not Reported	ng/mL	b4	1.523	0.124	Precision criteria for estimation of LLOQ	On
LLOQ accuracy	122	%	b5	#N/A	#N/A		
LLOQ precision	12.2	%					
Average Residuals	6	%					
Error in prediction: Best case	10	%				Preferred models (if any)	
Error in prediction: Expected	10	%					
Signal Min	4827	RLU				fingerstickmultiplier	1.00
Signal Max	72664	RLU				venousmultiplier	1.00
						plasmamultiplier	1.00
Outliers detected based on within-standard variance and manual detection	Outliers		ULOQ accuracy	100	%	srerun_lo	250
	Conc	RLU	ULOQ precision	9.0	%	srerun_hi	50000.0
	10	56319					
Statistically Detected ■	10	80350					
Manually Selected ■	50	46538					

Let me know if this is acceptable.

Sharada

=====

PRIVILEGED AND CONFIDENTIAL COMMUNICATION

IMPORTANT – This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which they are addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.

Theranos, Inc., 1601 S. California Ave, Palo Alto, CA 94304
650-838-9292 www.theranos.com

=====

From: Adam Rosendorff
Sent: Wednesday, January 15, 2014 6:24 PM
To: Erika Cheung
Cc: Sharada Sivaraman
Subject: RE: QC for EDISONS

Erika

The CV% at 18 ng/mL is way to high (~33%)- according to our validations it should be around 20%. The CV at the LLOQ (5) should not even be this high. This is messing up our QC ranges:

Level	mean	SD	CV%	2SD	lo	hi
Level 1	17.69	5.82175	32.9045	11.6435	6.05	29.34
Level 2	45.14	5.64918	12.5144	11.2984	33.84	56.44

I am concerned that the high value for level 1 is quite close to the lo value for level 2.

@Sharada- can you weigh in on a possible solution?

Thanks,

Adam

From: Erika Cheung
Sent: Wednesday, January 15, 2014 6:02 PM
To: Adam Rosendorff
Subject: RE: QC for EDISONS

I just figured out we didn't get the QC range established for the new set of Vitamin D. The data is attached for vitamin D under the tab QC. Can you send me this information too. I need the mean as well as the high low values. I'll create a standard place to put all the QC information now in the J drive.

Thanks,

Erika

From: Adam Rosendorff
Sent: Wednesday, January 15, 2014 5:44 PM
To: Erika Cheung
Subject: RE: QC for EDISONS

Erika

Do you happen to have the Vitamin D ranges? And can we put the active and prior QC data in a dedicated folder in CLIA?

Thanks,

Adam

From: Erika Cheung
Sent: Wednesday, January 15, 2014 5:40 PM
To: Adam Rosendorff
Subject: RE: QC for EDISONS

Beautiful, thanks Adam!

From: Adam Rosendorff
Sent: Wednesday, January 15, 2014 4:59 PM
To: Erika Cheung
Subject: QC for EDISONS

Level	Lo	Hi
Level1		101.39
Level2		419.28
Level3		759.36

Total Testosterone

Hepatitis C Virus

CTRL	average	SD	2SD	lo	hi
2 (POS)	2.55	0.40	0.79	1.76	3.34
3 (NEG)	0.94	0.13	0.27	0.67	1.21
5 (POS)	1.57	0.15	0.30	1.27	1.88

Free T4

Level	Lo	Hi
Level 1		1.008265
Level 3		4.28746

TSH

Daily QC	Mean	Low	High	CV%
Level 1	0.557	0.38	0.734	15.883
Level 2	4.549	3.403	5.695	12.591
Level 3	22.741	17.153	28.328	12.284

tPSA

	Mean	1 SD	2SD	Low	High	%CV
Level 1	1.06	0.19498	0.389959	0.67	1.45	18.44082
Level 2	4.39	0.607102	1.214205	3.17	5.60	13.83328
Level 3	35.97	7.246318	14.49264	21.48	50.46	20.14532

Adam Rosendorff, MD, FASCP

Laboratory Director

Theranos, Inc

(650) 856-4412 (Office)

(650) 823-4953 (Mobile)

(650) 852-9594 (Fax)

arosendorff@theranos.com